Key statistics
As of last trade, Panbela Therapeutics Inc (X70:MUN) traded at 0.38, 66.67% above the 52 week low of 0.228 set on Aug 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.38 |
Low | 0.38 |
Bid | -- |
Offer | -- |
Previous close | 0.38 |
Average volume | -- |
---|---|
Shares outstanding | 4.85m |
Free float | 4.85m |
P/E (TTM) | -- |
Market cap | 1.94m USD |
EPS (TTM) | -84.64 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 07:01 BST.
More ▼
Announcements
- First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
- Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
- Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
- Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
- Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
- Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
- Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
- Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
- Panbela Announces Poster Presentation at American Association for Cancer Research:
- Panbela Announces Transfer to OTCQB Market
More ▼